| US 7,531,651 B2 | ||
| Benzenesulphonate salt of a morpholine urea derivative for use as a CCR-3 antagonist in the treatment of inflammatory conditions | ||
| John Spencer Cook, Stevenage (United Kingdom); Robert Philip Landon, Stevenage (United Kingdom); Andrew John Walker, Stevenage (United Kingdom); and Mark Wilkinson, Stevenage (United Kingdom) | ||
| Assigned to Glaxo Group Limited, Greenford, Middlesex (United Kingdom) | ||
| Appl. No. 10/509,521 PCT Filed Mar. 27, 2003, PCT No. PCT/EP03/03345 § 371(c)(1), (2), (4) Date Jun. 10, 2005, PCT Pub. No. WO03/082293, PCT Pub. Date Oct. 09, 2003. |
||
| Claims priority of application No. 0207432.6 (GB), filed on Mar. 28, 2002. | ||
| Prior Publication US 2006/0089497 A1, Apr. 27, 2006 | ||
| Int. Cl. C07D 265/30 (2006.01); C07D 295/00 (2006.01); A61K 31/535 (2006.01) | ||
| U.S. Cl. 544—106 [544/63; 544/98; 544/107; 544/162; 514/228.8; 514/231.2; 514/237.8; 514/239.5] | 12 Claims |
1. A compound of formula (I):
 wherein A− is the benzenesulphonate (besylate) anion;
R is H or C1-6 alkyl; and
n is a number from 0.8 to 2.2.
|